Barts Cancer Institute and Cancer Research UK Barts Centre Director, Professor Nick Lemoine, was named in the 2019 Evening Standard Progress 1000 List, which recognises the most influential people in the capital.

Speaking of this recognition, Professor Lemoine said:

“I am humbled to be singled out amongst all the brilliant scientists and clinicians in the Barts Cancer Institute working to develop the new therapies and diagnostics that will radically improve outcomes for cancer patients in London and beyond.”

Professor Lemoine’s research interests lie in the genomics and molecular pathology of pancreatic cancer and the development of oncolytic virotherapy. Professor Lemoine and his team won the Pancreatic Cancer UK Grand Challenge Award to develop a type of immunotherapy, known as CAR T cell therapy, for which trials in patients are expected to begin next year. Professor Lemoine and his team hope that this type of immunotherapy will prove to be a promising treatment option for patients with pancreatic cancer.